PRESS RELEASE: Oska Pulse is making a real difference in people’s lives.
Oska Pulse is a registered medical device designed to reduce inflammation and accelerate healing, addressing the cause of pain. It is small, portable, non-invasive, and hands-free.
The exceptional performance of this revolutionary portable PEMF (pulsed electromagnetic field) medical device continues to impress. Oska Pulse, designed in Perth, Australia, and manufactured in the United States, has already assisted a large number of contented customers with pain relief, inflammation reduction, and wound healing.
The Oska Pulse is registered with the FDA as a Class 1 pain management device. It is also registered with the European Union (EU) and the Therapeutic Goods Administration of Australia as a CE/TGA Class IIA Medical device for enhanced healing of existing conditions, reduction of inflammation, and as an adjunct therapy in the treatment of osteoarticular inflammatory conditions, such as arthritis. Oska Pulse can be used alone or in conjunction with other therapies. Particularly useful for musculoskeletal injuries, wounds, arthritis, and chronic inflammatory conditions such as endometriosis, rheumatoid arthritis, and interstitial cystitis.
PEMF technology has an extensive history of clinical research.
We anticipate conducting Oska Pulse clinical evaluations in a number of prestigious German clinics.
One study on interstitial cystitis began in March 2023, and we are pleased that one of the foremost centres for interstitial cystitis is leading it.
In this research, Oska Pulse is being evaluated at the Department of Urology at the Clinic in Lueneburg. Dr Bjorn Kaftan, the principal investigator, senior physician, and urologist medical specialist, is the coordinator of the Centre for Interstitial Cystitis and Pelvic Pain. The trial has been authorised and registered at https://www.drks.de/DRKS00030890. ICA-Deutschland e. V. certified the Centre for Interstitial Cystitis and Pelvic Pain at the Clinic of Lueneburg in the spring of 2018 as Europe’s third centre of its kind.
The results of this clinical study will determine the efficacy of the Oska Pulse and PEMF in treating interstitial cystitis.
Our objectives for 2023 include conducting clinical trials for the treatment of CRPS (Complex Regional Pain Syndrome), Endometriosis, Rheumatoid Arthritis, and Psoriatic Arthritis.
Oska Pulse is committed to providing patients with a safe and effective alternative to traditional pain management methods and is proud to be at the forefront of pain relief and enhanced healing technology. The company’s ongoing clinical studies demonstrate its commitment to innovation and providing patients/customers with the best possible pain relief.
